ALDVIAdvicenneALDVI info
$1.16info0.19%24h
Global rank31515
Market cap$14.23M
Change 7d-7.79%
YTD Performance-60.53%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Advicenne (ALDVI) Stock Overview

    Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.

    ALDVI Stock Information

    Symbol
    ALDVI
    Address
    3ème étage 262Paris, 75008France
    Founded
    -
    Trading hours
    -
    Website
    https://www.advicenne.com
    Country
    🇫🇷 France
    Phone Number
    33 1 85 73 36 20

    Advicenne (ALDVI) Price Chart

    -
    Value:-

    Advicenne Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.16
    N/A
    Market Cap
    $14.23M
    N/A
    Shares Outstanding
    12.29M
    N/A
    Employees
    19.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org